Neuphoria Therapeutics terminated its Merck-partnered Phase 2 Alzheimer’s disease study of MK-1167, a move that puts the CHRNA7 modulator program’s future at risk. According to ClinicalTrials.gov, the trial status was changed to “terminated for business reasons” without a formal press release. The termination follows a contract partnership with Merck & Co. supporting the development of MK-1167 in Alzheimer’s. With the trial halted, investors are left to reassess the development path and the probability of future clinical studies for the CHRNA7 approach. The situation also highlights how late-stage modality bets can shift quickly when partnering companies reevaluate risk and capital allocation, even when program-specific scientific rationales remain intact. For the CHRNA7 platform, the immediate milestone is clarity on whether Neuphoria or Merck will restart studies, pivot indication focus, or pause development while looking for new financing or strategic alternatives.